Rankings Pharma & medtech Quantum-Si
Quantum-Si
49
15070100
A view of the same findings, not a new score. How it works
The model found several serious problems. That does not mean the stock will fall.
Biggest deductions
- Margin−14
- Delayed launch and layoffs−7
- Quality of growth−6
Strengths
- Net cash and runway+3
- Technical milestone+1
How the score is built
From 100 to 49, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 2 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 1.26 USD
- Median analyst target
- 1.90 USD
- Upside to median
- +50.8%
- Analysts
- 3
- Target range
- 1.00 – 3.95 USD
- 52-week change
- −41%
- P/E (trailing)
- n/a
- Forward P/E
- n/a
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 4 findings−28 of −30
- −14MarginRevenue USD 1.6m TTM vs an operating loss of 92m and operating cash flow of -92m. The loss has been 95-114m a year since 2021 with no sign of operating leverage.
- −6Quality of growthRevenue fell 53% TTM and 42% in Q2 2026 (USD 344,000 vs 591,000) in the transition from Platinum to Proteus. Platinum has not gained a commercial foothold after three years on the market.
- −5Capital allocationThe company has spent over USD 500m since the SPAC listing in 2021. The share count has risen 31% in a year (USD 95m in share issuance in 2025 and 47m TTM). ROIC −28%.
- −3MoatSingle-molecule protein sequencing on a semiconductor chip is unique and patent-protected, and 18 of 20 amino acids can now be detected. The technology is not commercially proven, however, and customers can still use mass spectrometry (Thermo Fisher, Bruker) or affinity platforms (Olink, SomaLogic).
Price
Today's multiples against the company's own history and its peers. · 2 findings−8 of −35
- −5Multiples vs own historyEV has risen from USD 11m at the end of 2025 to about 173m (EV/Sales 108 vs 4.6 in 2025 and 24-66 in 2023-2024). P/B 1.9 vs 0.7-1.8 in 2022-2025, i.e. the top of the range after a price rise of about 90% in two months.
- −3Peers and absolute levelThe market cap of USD 339m is approx. 2x net cash (167m) for a product that will launch no earlier than Q2 2027. Pre-commercial proteomics companies such as Nautilus Biotechnology typically trade close to cash.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 4 findings−15 of −35
- −7Delayed launch and layoffsThe Proteus launch has been postponed to Q2 2027 (previously early access in summer 2026 and commercial launch before year-end) because an extra design cycle is needed. At the same time approx. 20% of employees are being laid off. CEO: going into production with the current design would carry 'more execution risk than we are comfortable with'.
- −2Listing risk (Nasdaq)Nasdaq notice 23/7-2026 for closing price below USD 1; deadline 19/1-2027. The price is now USD 1.55, so compliance has probably been regained or is close, but the share has been below USD 1 for large parts of 2026.
- −4DilutionThe share count is +31% over a year, and the company has used ATM and directed issues when the price rose. With spending of about USD 80m a year and a launch in 2027, capital must be raised again before breakeven, probably after the price rise.
- −2Governance (two share classes)19.9m B shares with enhanced voting rights alongside 198.9m A shares give the founder control, which limits minority shareholders' influence.
Plus
Only documented strengths. · 2 findings+4 of +15
- +3Net cash and runwayCash and securities of USD 169.9m at 30/6-2026, debt 3m, and management guides runway into Q4 2028 after savings of 12m per year.
- +1Technical milestone15/9-2026: detection of 18 amino acids on integrated Proteus instruments with a development kit; target of all 20 in 2026.
Caveats
What the score does not capture, or where the data is weak.
The price has risen from about USD 0.8 (50-day average) to USD 1.55 on 2/10-2026 (RSI 87), so the market cap is now about USD 339m (≈DKK 2,233m) vs Nordnet's DKK 1,422m at 1/10. No specific news found for the latest price jump beyond the 18-amino-acid announcement on 15/9. Cash = cash and securities (USD 169.9m at 30/6). Industry: life science tools (protein sequencing) fit closest under 'Medicine & medtech'. Insider trades and warrants not reviewed in detail. Only 3 analysts.
Also in Pharma & medtech
The highest scores in the same industry.
